- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04891640
Réduction biologique et capture des résultats des enfants et de la fréquence des poussées dans la spondylarthrite juvénile (BACK-OFF JSpA)
Réduction biologique et capture des résultats des enfants et de la fréquence des poussées dans la spondylarthrite juvénile (BACK-OFF JSpA)
This randomized pragmatic trial will generate knowledge about strategies used to de-escalate tumor necrosis factor inhibitor (TNFi) therapy in patients with juvenile spondyloarthritis with sustained inactive disease and are treated at one of the 31 participating pediatric healthcare systems. This open label study will be conducted in the setting of routine clinical care and will compare the risk and timing of flare (Aim 1) and patients' lived experiences (Aim 2) across three arms.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This project is a prospective, 12-month (+/- 1 month) pragmatic randomized trial embedded within routine clinical care. Children with spondyloarthritis who have maintained inactive disease on a clinically prescribed standard dosing of a TNFi for 6 months or longer will be eligible for enrollment. Children will be randomized to one of the following alternative approaches: continued fixed standard dosing (arm 1), fixed longer dosing intervals of TNFi (arm 2), or stopping TNFi (arm 3). The recommended visit frequency is every 3 months (+/- 1 month) through the study endpoint at 12 months (+/- 1 month). After subjects have followed their treatment assignment for 12 months (+/- 1 month), those who have not flared may modify their treatment regimen as per shared decision making between themselves and the treating physician. All participants will be monitored for 24 additional months for long-term outcomes after the intervention period.
Type d'étude
Inscription (Réel)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 1E8
- The Hospital for Sick Children
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35294
- University of Alabama at Birmingham
-
-
Arizona
-
Phoenix, Arizona, États-Unis, 85006
- Phoenix Children's
-
-
California
-
Los Angeles, California, États-Unis, 90027
- Children's Hospital Los Angeles
-
Palo Alto, California, États-Unis, 94304
- Stanford University
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80045
- Children's Hospital of Colorado
-
-
Delaware
-
Wilmington, Delaware, États-Unis, 19803
- Nemours Children's Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20010
- Children's National Health System
-
-
Florida
-
Orlando, Florida, États-Unis, 32827
- Nemours Children's Health
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46202
- Riley Hospital for Children at IU Health
-
-
Iowa
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa Stead Family Children's Hospital
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, États-Unis, 55455
- University of Minnesota Masonic Children's Hospital
-
-
Missouri
-
Kansas City, Missouri, États-Unis, 64108
- Children's Mercy Hospital
-
St Louis, Missouri, États-Unis, 63110
- St. Louis Children's Hospital
-
-
New York
-
New York, New York, États-Unis, 10021
- Hospital for Special Surgery
-
Queens, New York, États-Unis, 11040
- Cohen Children's Medical Center
-
-
Ohio
-
Akron, Ohio, États-Unis, 44302
- Akron Children's Hospital
-
Cincinnati, Ohio, États-Unis, 45229
- Cincinnati Children's Hospital Medical Center
-
Columbus, Ohio, États-Unis, 43205
- Nationwide Children's Hospital
-
-
Oregon
-
Portland, Oregon, États-Unis, 97227
- Randall Children's Hospital at Legacy Emanuel
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, États-Unis, 19104
- The Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- UPMC Children's Hospital of Pittsburgh
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Vanderbilt Children's Hospital
-
-
Texas
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern Medical Center
-
Houston, Texas, États-Unis, 77030
- Texas Children's Hospital - Baylor College of Medicine
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84113
- Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, États-Unis, 98105
- Seattle Children's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
Males or females age 8 to 21 years
-
Juvenile SpA diagnosis:
• Symptom onset before their 16th birthday:
o International League of Associations for Rheumatology (ILAR) criteria for juvenile idiopathic arthritis enthesitis-related arthritis subtype
OR;
• Symptom onset before their 18th birthday:
o Pediatric Rheumatology International Trials Organization (PRINTO) revision of the ILAR criteria enthesitis spondylitis-related JIA
- Peripheral arthritis and enthesitis, or
- Arthritis or enthesitis, plus ≥3 months of inflammatory back pain and sacroiliitis on imaging, or
- Arthritis or enthesitis plus 2 of the following: (1) sacroiliac joint tenderness; (2) inflammatory back pain; (3) presence of HLA-B27 antigen; (4) acute (symptomatic) anterior uveitis; and (5) history of a SpA in a first-degree relative.
- If peripheral arthritis is present, it should persist for at least 6 weeks.
-
Currently taking one of the following TNFi therapies (Adalimumab, Certolizumab, Etanercept, Golimumab, Infliximab, or TNFi biosimilar) at standard doses
-
Have reached a clinically inactive disease state for a minimum of six months, as determined by treating physician
-
English speaking or Spanish speaking
-
Subject's treating physician recommended that he/she is a good candidate to participate in the study, which may include a modified therapy
-
Interested and willing to de-escalate TNFi therapy
Exclusion Criteria:
1) History of inflammatory bowel disease, history of uveitis that was not adequately controlled with localized ophthalmic treatment or psoriasis that pre-dates the start of TNFi therapy or psoriasis that started after TNFi therapy and has required more than topical therapy for control
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: TNFi Standard Therapy
Continue fixed standard treatment (i.e., no change from current therapy) |
Participants randomly assigned to this arm will continue taking their TNFi medication as currently prescribed. |
|
Expérimental: TNFi fixed longer dosing intervals
Fixed longer dosing intervals of TNFi (i.e., increased time between doses) |
Participants randomly assigned to this arm will increase the time between TNFi medication doses.
|
|
Expérimental: TNFi Therapy Withdrawal
Stop TNFi treatment |
Participants randomly assigned to this arm will stop TNFi medication. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Juvenile Spondyloarthritis (JSpA) flare
Délai: 12 months
|
JSpA flare is defined as clinically meaningful worsening in ≥3 of the following: caregiver/patient assessment of well-being, physician assessment of disease activity, caregiver/patient assessment of pain, physical function, and active joint count. Meaningful change for well-being, disease activity, and pain are an increase of ≥2 on visual analogue scale (range 0-10 with higher scores indicating poorer well-being, higher disease activity, and higher magnitude of pain). Meaningful change in function is defined as ≥3 unit change in the PROMIS mobility or upper extremity T-scores. The Patient-Reported Outcomes Measurement Information System (PROMIS) short forms include 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation of 10. Active joint count is defined as the number of joints with swelling or, in the absence of swelling, limitation of motion accompanied by pain or warmth as per the physician examination. |
12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pain interference (as measured by the PROMIS short form)
Délai: 12 months
|
Pain interference (as measured by the PROMIS short form) of children with spondyloarthritis in the three treatment arms. The PROMIS short form is a validated questionnaire that measures the self-reported consequences of pain on relevant aspects of a person's life.The PROMIS short form includes 8 questions and a T-score of '50' represents the healthy population mean score with standard deviation equal to 10. |
12 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 21-018442
- : GRT-00001036 (Autre subvention/numéro de financement: PCORI)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .